Binger Straße 173
D-55216 Ingelheim
Germany
Project leader
 |
|
Co-Project leader
 |
|
Project staff
 |
|
|
|
|
|
 |
|
|
|
Institute presentation
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with high unmet medical need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on six major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Infectious diseases, Oncology and Respiratory diseases.